Predicting the probability of death

"This is pretty cool but also scary and hopefully somewhat useful"

21-Jun-2021 - Scientists from deCODE genetics have developed a predictor based on protein measurements in blood samples that predicts the time to all-cause death better than traditional risk factors. In a paper published in Communications Biology, scientists from deCODE genetics,a subsidiary of Amgen, ...

GENALICE and deCODE Genetics enter into a partnership for population wide genomic analysis

28-Jul-2014 - GENALICE announced it is partnering with deCODE Genetics to facilitate the large-scale testing of its unique DNA data processing software solution, GENALICE MAP. After a first successful round of evaluating GENALICE MAP on speed and quality, both parties agreed to extend the evaluation to include ...

Scientists present the largest-to-date genetic snapshot of Iceland 1000 years ago

19-Jan-2009 - Scientists at deCODE genetics have completed the largest study of ancient DNA from a single population ever undertaken. Analyzing mitochondrial DNA, which is passed from mother to offspring, from 68 skeletal remains, the study provides a detailed look at how a contemporary population differs from ...

deCODE Discovery Sheds Light on Risk of the Most Common Form of Skin Cancer

Latest discoveries add to understanding of individual risk of basal cell carcinoma, and are integrated into the deCODEme™ personal genome analysis scan

15-Oct-2008 - Scientists at deCODE genetics reported the discovery of common versions of two single-letter variations in the human genome (SNPs) that confer risk of basal cell carcinoma (BCC). Unlike the four sets of SNPs previously found by deCODE to confer risk of BCC and cutaneous melanoma, those are not ...

deCODE and Illumina Form Alliance to Develop and Commercialize DNA-based Diagnostics

Companies to initiate work on molecular diagnostics for the risk of heart attack, type 2 diabetes and breast cancer

17-May-2006 - deCODE genetics and Illumina, Inc. announced the formation of a strategic alliance under which the companies plan to co-develop and commercialize DNA-based diagnostic tests in several major disease areas. The alliance will employ Illumina's platform for high-multiplex single-nucleotide ...